Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial

Objective We used the Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) data set to examine the impact of presence of enthesitis, dactylitis, nail disease and/or psoriasis on treatment response in patients with early psoriatic arthr...

Full description

Bibliographic Details
Main Authors:	Helliwell, PS, Mease, PJ, Kavanaugh, A, Coates, LC, Ogdie, A, Deodhar, A, Strand, V, Kricorian, G, Liu, L, Collier, D, Gladman, DD
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2022

Similar Items

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
by: Mease, P, et al.
Published: (2018)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

Psoriatic arthritis
by: FitzGerald, O, et al.
Published: (2021)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Classification and outcome measures for psoriatic arthritis
by: Leung, Y, et al.
Published: (2018)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
by: Mease, PJ, et al.
Published: (2019)

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
by: Coates, LC, et al.
Published: (2021)

Psoriatic arthritis: prospects for the future
by: Hackett, S, et al.
Published: (2022)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
by: Gladman, DD, et al.
Published: (2018)

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
by: Coates, LC, et al.
Published: (2022)

Sex-specific challenges in patients with psoriatic arthritis (PsA): preliminary results from a systematic literature review (SLR)
by: Coates, LC, et al.
Published: (2021)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
by: Mease, PJ, et al.
Published: (2020)

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate
by: Coates, LC, et al.
Published: (2023)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
by: Soriano, ER, et al.
Published: (2023)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
by: Weinstein, SM, et al.
Published: (2021)

Screening/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey
by: Song, K, et al.
Published: (2023)

Usage of C-reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe
by: Ogdie, A, et al.
Published: (2022)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
by: Leung, YY, et al.
Published: (2020)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
by: Tillett, W, et al.
Published: (2017)

Methotrexate in psoriasis and psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
by: Coates, LC, et al.
Published: (2022)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
by: Strand, V, et al.
Published: (2022)

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
by: Holland, R, et al.
Published: (2018)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
by: Strand, V, et al.
Published: (2024)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
by: Tillett, W, et al.
Published: (2020)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
by: Coates, L, et al.
Published: (2019)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
by: Leung, Y-Y, et al.
Published: (2023)

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
by: Leung, Y-Y, et al.
Published: (2020)

Considerations for the definition of remission criteria in psoriatic arthritis
by: Mease, P, et al.
Published: (2017)

What should be the primary target of "treat to target" in psoriatic arthritis?
by: Coates, LC, et al.
Published: (2018)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
by: Coates, L, et al.
Published: (2016)

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis
by: Leung, YY, et al.
Published: (2021)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design
by: Rombach, I, et al.
Published: (2021)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
by: Coates, L, et al.
Published: (2017)

Current concepts and unmet needs in psoriatic arthritis
by: Mahmood, F, et al.
Published: (2017)

Outcome measures in psoriatic arthritis: where next?
by: Hackett, S, et al.
Published: (2022)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus‐based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis
by: Coates, L, et al.
Published: (2017)

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire
by: Coates, LC, et al.
Published: (2020)